BATON ROUGE, LA–(April 18, 2017) – OncBioMune Pharmaceuticals, Inc. (OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the upcoming submission of the Anti-D immunoglobulin product marketed as KamRho® by Kamada and licensed by OncBioMune for the Mexican market. Documentation is being finalized with submission to COFEPRIS, Mexico’s equivalent of the U.S. Food and Drug Administration, expected by the end of the month. Anti-D immunoglobulin is listed on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system.

KamRho® is a sterile non-pyrogenic aqueous solution, containing 150 μg/mL of immune globulin anti-D administered intravenously. It is indicated for the suppression of Rh immunization in non-sensitized Rho (D) negative women delivering an Rho positive baby, or when the baby’s Rh type is unknown. It is also indicated for suppression of Rh immunization after spontaneous or induced abortions, threatened abortion associated with maternal bleeding, amniocentesis, chorionic villus sampling, ruptured tubal pregnancy, and significant abdominal trauma.

Amongst other things, Anti-D immunoglobulin is a treatment used to prevent Rhesus Disease, a disease caused by a specific mix of blood types between an unborn baby and the pregnant mother. The anti-D immunoglobulin neutralizes any RhD positive antigens that may have entered the mother’s blood during pregnancy. Injections are often required during and following birth.

“The submission to COFEPRIS is a great milestone for us in our initiatives to commercialize new products in Mexico on a regular basis that can represent substantial revenue streams. The submission in the coming weeks keeps us on track to anticipate regulatory approval during the fourth quarter and immediate sales in 2018,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “In the spirit to further expand our relationship with Kamada, a trip to Israel is being planned for early in May to meet with Kamada leadership to discuss the additional licensing agreements as well as extending territorial rights throughout Central and Latin America correspondingly.”

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals’ actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals’ need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical’s vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact:

OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer
akucharchuk@oncbiomune.com